stable at 3 years (29%). Patients reporting persistently poor SQ had significantly more depressive symptomatology and lower global quality of life.
Conclusion
Because self-reported poor SQ is related to poorer global quality of life, these results emphasize the need for further studies to find suitable treatment options for poor SQ in transplant recipients.
Background
After a successful transplantation, loss of sleep quality (SQ) typically reduces' recipients' quality of life and may impair survival. However, during follow-up, sleep quality (SQ) self-reports have rarely been collected via standardized protocols. To be feasible, the measurement has to be simple, valid and reliable. Therefore, to differentiate poor from good sleepers, we used a single item from the sleep subscale of the Kidney Disease and Quality of Life-Short Form (KDQoL-SF): "On a scale from 0-10, how would you evaluate your sleep?" Scores of 0-5 were classed as poor; 6-10 indicated good SQ. This item is not yet part of a standardized protocol, and sleep quality is not yet a standardized follow-up criterion.
Poor sleep quality (SQ) is common in hemodialysis patients (49%-53% prevalence) [1, 2] . Kidney transplantation is expected to correct most kidney disease-related abnormalities of the kidney disease and significantly improve the patients' health. However, a 2011 study reported high (31%) prevalence of poor SQ after kidney transplantation [3] . This may reflect a serious risk regarding patient survival. The Dialysis Outcomes and Practice Patterns Study collected SQ data from 11351 patients in 308 dialysis units across seven countries and reported a 16% higher relative risk of mortality in hemodialysis patients with poor SQ compared to good sleepers [1] . Such a strong link with overall wellbeing and health indicates an equally strong need to detect and understand poor SQ as a post-transplantation health outcome. Patientreported outcomes (PROs) including SQ are becoming extremely important indicators of the quality of patient care [4] . To date, however, no studies have used PROs (e.g., sleep quality) simultaneously in kidney, heart, liver and lung transplant patients to monitor global quality of life and survival. Data on SQ in kidney, heart, liver and lung transplant patients are scarce, and longitudinal studies are even more so. Therefore, based on data from the Swiss Transplant Cohort Study, the current analysis had three aims: (1) to detect and compare changes in SQ in kidney, heart, liver and lung transplant recipients over time (pre-, 6, 12, 24, and 36 months post-transplant); (2) to compare solid organ transplant recipients groups (kidney, heart, liver and lung) with persistent poor SQ over time; and (3) to compare global quality of life and survival over time (until 3 years post-transplant) in subjects with persistently poor SQ as opposed to those with consistently good and variable SQ.
Materials and methods

Design, sample and setting
For this study we used data from the Swiss Transplant Cohort Study, a prospective open cohort study including 1173 patients transplanted in one of the six Swiss transplant centers (Lausanne, Geneva, Basel, Zürich, Bern, St. Gallen). Details of that study are published elsewhere [5] . Kidney, heart, liver and lung transplant recipients were eligible if they were aged 18 years Global quality of life was assessed with a visual analogue scale from 0 (worst imaginable quality of life to 100 (best imaginable quality of life). This scale is both widely used and validated for use in German-language settings [6, 11] where it has shown high levels of validity and reliability [12] . The mean score for global quality of life in the general German population was 77.1±17.8 [13] . We used this variable as an outcome as it measures a broad construct of health (a summary of numerous health issues facing transplant recipients) that is close to the transplant recipient's perspective [12] . Survival was defined as the estimated fraction of transplant recipients who would survive over the six years of the study period, it was used as a function to estimate the probability that transplant recipients with poor SQ would eventually differ from those with consistently good or variable SQ after transplantation.
Statistical analysis
Descriptive analyses of sample characteristics were performed using frequencies, proportions, measures of central tendency (means, medians) and dispersion (standard deviations, interquartile ranges) as appropriate for measurement levels and distributions. Differences in demographic and clinical characteristics among organ groups were screened using Chi-square or Wilcoxon rank-sum tests.
Changes in poor SQ over time for the various organ recipient groups and the overall sample were depicted graphically. They were also modeled via logistic regression analyses using generalized estimating equations to account for the repeated measures [14] , and controlling for organ group, age, gender, depressive symptomatology, co-morbidities, immunosuppressive regimen and the time that elapsed between baseline measurement (the pre-transplant psychosocial questionnaire) and transplantation. The model presented was adjusted by retaining only significant covariates.
Two sub-analyses were also performed. The first used an interaction between organ group and time category to generate odds ratio comparisons based entirely on pre-transplant data. The second, performed using post-transplant data, incorporated time as a continuous variable to allow the estimation of linear trends over the post-transplant period. To examine the possible effect of missing follow-up data on model stability, analyses were also performed using a Last-Observation-Carried-Forward (LOCF) imputation strategy.
For our second and third aims, we divided patients into two groups based on their longitudinal sleeping patterns: those who had persistent poor SQ and all others. As at least two posttransplant measurement points were needed to define patients with persistent poor SQ, inclusion was limited to patients who survived at least 1 year post-transplant.
Differences between patients with persistently poor SQ versus those with consistently good or variable SQ were explored via descriptive analyses, and using Chi-square, Wilcoxon ranksum tests, or Kaplan-Meier estimates as appropriate. We determined both global quality of life and survival via Kaplan Meier analyses, and compared the results with those with consistently good or variable SQ. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) software. The alpha level was set at 5%.
Results
Sample characteristics overall
As of February 2, 2012, the Swiss transplant cohort study included 1597 patients, of whom 1173 fulfilled the current study's inclusion criteria: 770 (65%) kidney, 201 (18%) liver, 123 (10%) lung and 79 (7%) heart transplant candidates. Fig 1 depicts the overall sample size and the number of included respondents per organ group at each data collection point. Demographics and clinical characteristics of the 1173 transplant recipients included in the analyses are provided in Table 1 . At pre-transplant measurement, the average patient age was 50.1±13.2 years; almost two-thirds (65.5%) were male; and most (66.1%) were married or living with a partner. The median period between pre-transplant assessment and transplantation was 7.7 ±9.6 months.
The follow-up time ranged from 18 months to 7.1 years, with a median of 4.1 years (interquartile range 2.0). Of the 1173 patients included in the study at the pre-transplant measurement, 894 (76.2%) had available data over 36 months. One hundred, eight (9.2%) patients had died by the end of the study.
Of the 765 kidney insufficient patients, 16% (N = 119) were transplanted pre-emptively (estimated GFR (eGFR) was 10 ml/min/1.73m 2 ), 69% (N = 531) were on hemodialysis and 15% (N = 115) on peritoneal dialysis. The mean time on dialysis was 4.0±5.0 years. The eGFR at 36 months was 55 ml/min/1.73m 2 post-kidney transplantation and 72 ml/min/1.73m 2 postliver transplantation. The pre-liver-transplantation MELD score was 20±9 and the pre-hearttransplantation Ejection Fraction was 24.4±13.0%. 
Sleep quality from pre-to 3 years post-solid organ transplantation
Changes of poor sleep quality between organ groups over time Fig 2 shows the percentages of patients with poor SQ at each data collection point. Pre-transplant, 38% of the sample reported poor SQ. At 24 months post-transplant, poor SQ was reported at its lowest level (26%). Fewer heart, kidney and liver transplant recipients reported poor SQ at six months compared to pre-transplant (Table 2 ). For the kidney and liver transplant groups, this improvement continued until the 1-year measurement. Overall, as illustrated in Table 3 , patients' odds of poor SQ were higher at baseline (OR 1.45; 95%CI: 1.21-1.74) and 6 months post-transplant (OR 1.44; 95%CI: 1.21-1.72) compared to 24 months post-transplant. Pre-transplant liver patients reported the highest occurrence of poor SQ (50%), followed closely by heart transplant candidates (49%). Both these groups differed significantly from their lung transplant (32%) and kidney transplant (34%) counterparts (Table 3) (Table 4) . Other organ recipient groups showed no statistically significant changes over time. In terms of estimates and inferences, replacing missing values by imputing the last observed values yearly until the end of the observation period only moderately (not statistically significant) affected the results in any of the tables.
Sample characteristics and correlates for transplant recipients with persistent poor SQ Table 5 shows the characteristics of the overall sample at 6 months post-transplant, alongside those of persistent poor SQ and of all others (those with consistently good or variable SQ). The persistently poor SQ group accounted for 10% of the sample (N = 107; 10.4%). Poor SQ was more prevalent in patients with lower education (p = 0.03) and in those with more depressive symptoms (p = < .0001).
Global quality of life and Survival for Patients with persistent poor SQ
Pre-transplant, the global quality of life rating was 55.9±22.6; 6 months post-transplant, it increased to 74.3±17.7. Graft recipients with persistently poor SQ over time had a significantly lower mean global quality of life (59.7±21.5; p = < .0001) compared to those with consistently good or variable SQ. This result was consistent when controlling for organ group, age, gender, comorbidities and time between inclusion in the Swiss Transplant Cohort Study and transplantation. Missing data over time did not change the results (as determined by a sensitivity analysis using a last observation carried forward imputation method). At 6 years post-transplant, survival probability was 0.83 for those with consistently good or variable SQ and 0.79 for patients with persistent poor SQ (not significant). 
Discussion
To the best of our knowledge, the current work represents the largest study to date to simultaneously investigate self-reported SQ in heart, lung, liver and kidney transplant groups using a single protocol. We found that poor SQ affected roughly one-third of transplant recipients throughout the measurement period, but generally improved from pre-transplant until 1 year post-transplant. Significant differences in perceived SQ were observed between organ groups. As reported in previous studies, poor SQ is common pre-and post-transplant; however, those studies were limited regarding follow-up periods and sample sizes, and used various SQ assessment methods. [15, 23, 24] and 32-54% in lung transplant recipients [15, 25] . Measured with the Pittsburgh Sleep Quality Index the prevalence of poor SQ in the general population ranges from 22% [26] to 45% [27] . As there are no prevalence data of poor SQ assessed with the single SQ item we cannot conclude that our prevalence is higher than in the general population. The most appropriate conclusion drawn from these results is the comparison of the prevalence of poor SQ across organ transplant groups and over time.
Changes in poor sleep quality over time
The improvement indicated from pre-to post-kidney transplantation confirms the findings of previous studies [21] . For example, one recent study showed that 46% of kidney transplant recipients experienced a clinically relevant improvement in overall sleep quality, while 21% experienced a clinically relevant deterioration [21] over 5 years of follow up. Over time, kidney and liver transplant recipients showed a significant decrease in poor SQ. The drop might be connected with the normalization of life with a transplanted organ and return to work [28] . Compared to heart and lung groups [29] , the fear of rejection and the frequency of follow-up visits are normally reduced at 36 months post-kidney and liver transplantation. Liaveri et.al.'s study in renal transplant recipients reported improved quality of life after transplantation; however this benefit does not seem to extend to sleep quality [30] . In that case, sleep quality was affected by frequency of post-traumatic stress symptoms, depression, restless leg syndrome, high diastolic blood pressure, and pain [30] .
One hypothesis to explain these connections is that fatigue (reported prevalence post-kidney transplantation: 40%-50% [31] ) interferes with perceived sleep quality. It also limits a person's ability to carry out ordinary daily activities, with a bidirectional impact on sleep [32] . Daytime sleepiness improves [22] after kidney transplantation; however, those for whom it persists are more prone to immunosuppression non-adherence [33] . No [22] or little improvement [34] was found with objective measurements such as melatonin secretion or circadian rhythms.
No significant change over time was found in heart and lung transplant recipients. Their slope showed fluctuation that could represent the health instability in these transplant recipients. In a qualitative study the recipients' uncertainty reflected their complex medication regimens, unpredictable future health/prognosis, and complex role and identity challenges [35] . Heart and lung transplant recipients' medication regimen may also be more complex than those of liver and kidney recipients [36, 37] .
Characteristics of transplant recipients with persistent poor SQ over time
Transplant recipients with persistent poor SQ (10% of the sample) need to consult with a sleep medicine expert. Occasionally, not getting enough sleep is completely normal; however, over months and years, poor SQ results in a suffering trajectory. E.g., we found that transplant Explanation: Logistic regression model predicting poor SQ (N = 1173), controlling for gender and depressive symptomatology and including an interaction between organ groups and continuous time.
Because of nonlinearities between pre-and post-transplant time-points, only post-transplant data were included. Odds rations represent regression slopes over time for the different organs.
https://doi.org/10.1371/journal.pone.0185036.t004
Sleep quality from pre-to 3 years post-solid organ transplantation recipients with persistent poor SQ score significantly higher on the depressive symptomatology scale. This association mainly corroborates previous findings [38, 39] in transplant recipients. Among patients with lower educational levels and more depressive symptomatology, the predisposition for poor SQ has previously been confirmed by Patel et. al. [40] and in a review by Tsuno et.al. [41] . Transplant recipients whose poor SQ persisted over extended periods had a significantly lower mean global quality of life compared to those with consistently good or variable sleep quality. A study including patients suffering from chronic illnesses such as coronary artery disease showed that both sleep quality and sleep quantity impact these patients´quality of life [42] . This is congruent with a recent review´s finding that pronounced persistent poor sleep is a major risk for psychiatric, cardiovascular, metabolic or hormonal co-morbidity and mortality [43] .
We found no increased mortality risk among transplant recipients whose poor SQ persisted over time. Poor SQ, depression and poor global quality of life commonly co-occur in transplant recipients in ways that suggest bi-directional influence. Evidence that poor SQ is part of a cluster of symptoms has been found in cancer patients [44] . However, further studies are needed as a recent study (N = 152 renal transplant recipients) reported an amelioration of renal function post-transplantation that improved several aspects of quality of life, but with no beneficial effect on self-reported sleep [30] . Finally, as the high prevalence of poor SQ is an increasing public health issue [45] , its associations with poorer outcomes indicate a need for regular assessment.
Clinical relevance and possible interventions
Of the sleep assessment methods currently available, self-reporting is the most accessible, least expensive and simplest to integrate into daily clinical practice [1, 3] . Our analysis showed no Sleep quality from pre-to 3 years post-solid organ transplantation association between poor SQ and lower survival; however, the dialysis Outcome and Practice Patterns Study associated poor SQ with higher mortality [1] . Therefore, it is worth integrating this simple question into standard follow-up care while monitoring other parameters. If during the follow-up visit a score >6 on the single-item self-report of SQ is given, a more in-depth questionnaire or a sleep assessment-asking among other things, about sleep aids should follow. Transplant recipients are educated not to take over-the-counter medicines or herbal supplements without first discussing them with the transplant clinician [46] . In the general population, use of over-the-counter sleep aids (e.g., herbal pills, melatonin or antihystamines) is common [47] . However herbal formulations with an anxiolytic and sedative effect might precipitate liver failure [48] . Even in healthy people, sleep aids are always potentially toxic to the kidneys and liver [49] , with common adverse effects including daytime somnolence or decreased alertness [50] . Additional risks have to be acknowledged for all transplant patients. To deal with the problem of persistent poor sleep quality, though, it is crucial to know which factors or combinations of factors influence patients' perceptions of their SQ. To understand these factors and move forward, system-level improvement is needed in transplant recipient follow-up care.
Strength and limitation
A limitation of the Swiss Transplant Cohort Study, is that, in the interests of their instrument s overall feasibility, its designers could include only a very short and quick scale on SQ. Compared to a well-established tool such as the Pittsburgh Sleep Quality Index, our single-item solution is a weak measurement of sleep quality. As a counterpoint, the Swiss Transplant Cohort Study includes a large sample of solid organ transplant recipients reporting sleep quality issues over time.
One further weakness is that the Swiss Transplant Cohort Study psychosocial questionnaire does not permit investigation of specific sleep disorders such as restless leg syndrome, periodic limb movement, or sleep apnea. However this single-item scale´s validity has been confirmed in kidney studies, suggesting further uses in the clinical context of organ transplantation [1] [2] [3] . This single-item SQ measurement could easily be incorporated in ambulatory clinic follow-up care for transplant recipients.
Conclusion
Sleep quality improved following transplantation; but poor sleep quality was prevalent in kidney, heart, liver and lung transplanted patients. Therefore, SQ should be assessed routinely in solid organ transplant recipients.
